Stock search

Ticker or company name

Compare stocks

Market: US

  • VRTXVertex Pharmaceuticals
  • REGNRegeneron Pharmaceuticals
  • GILDGilead Sciences

Add stock

Ticker or company

Summary

VRTX
Vertex Pharmaceuticals
$537,79Down −0,15%
Year: Up +24%
72/100Best scoreRatio would consider buying
Open stock page
REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100Ratio would watch
Open stock page
GILD
Gilead Sciences
$167,58Down −0,30%
Year: Up +34%
25/100Ratio would not consider buying
Open stock page

Verdict

VRTX has the best score (72). REGN grows revenue the fastest. REGN is the cheapest by forward P/E. REGN has the lowest debt load. VRTX has the highest net margin. GILD has 5 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckVRTX5 ✓ 3 — 1 ✕REGN5 ✓ 2 — 2 ✕GILD1 ✓ 2 — 5 ✕
P/E vs its history33,720,5—
P/E vs industry33,720,5—
Forward P/E27,213,8n/a20,9
Revenue growth, YoY+10,5%+18,6%+6,5%
EPS growth, YoY+9,3%+8,3%—
Net margin30,7%28,5%−12,5%
Net debt / EBITDA−0,6−1,4—
Free cash flow$3,20 bn$3,83 bn$13,8 bn
Share count over a year−0,9%−1,5%−0,2%
Cash runwayn/anot neededn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterVRTXTTMREGNTTMGILDTTMIndustry medianTTM
P/E TTM ↓Worst: 33,7Best: 20,5n/a42,1
Forward P/E ↓Worst: 27,2Best: 13,820,918,7
PEG ↓Worst: 3,0Best: 1,2n/a4,1
P/S TTM ↓Worst: 10,3Best: 5,86,76,6
EV/EBITDA ↓Worst: 29,6Best: 18,218,828,2
P/FCF ↓Worst: 41,927,2Best: 15,126,0

Price, %

  • VRTXn/a
  • REGNn/a
  • GILDn/a

Returns

Best WorstNo mark — in between

PeriodVRTXREGNGILD
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

VRTXREGNGILD
Share of “buy”82%Worst: 72%Best: 83%
Beat the forecastWorst: 1 of 4Best: 4 of 4Best: 4 of 4
Average “surprise”Worst: −1,5%Best: +16,8%+6,9%
Insiders over 12 monthssales $129 msales $57,9 msales $102 m

Details are on each stock page.